Table 2.
Crude risks for non-ICH MB and ICH
| Non intracranial haemorrhage | Intra cranial haemorrhage | |||||
|---|---|---|---|---|---|---|
| Factor | non-ICH MB, n = 17 | Crude OR non-ICH MB | 95% CI | ICH, n = 16 | Crude OR ICH | 95% CI |
| Gender (female), n (%) | 12 (70.6) | 1.13 | 0.39–3.28 | 11 (68.8) | 1.04 | 0.35–3.04 |
| Atrial fibrillation, n (%) | 7 (41.2) | 2.73 | 1.01–7.37 | 2 (12.5) | 0.56 | 0.12–2.50 |
| Hypertension, n (%) | 13 (76.5) | 1.8 | 0.58–5.62 | 11 (68.8) | 1.22 | 0.42–3.57 |
| Chronic Kidney Disease*, n (%) | 1 (5.9) | 0.37 | 0.05–2.81 | 1 (6.3) | 0.39 | 0.05–3.01 |
| Diabetes mellitus, n (%) | 4 (23.5) | 1.09 | 0.35–3.43 | 4 (25.0) | 1.18 | 0.37–3.75 |
| Ischemic stroke in medical history, n (%) | 9 (52.9) | 4.85 | 1.82–12.94 | 4 (25.0) | 1.44 | 0.45–4.57 |
| Heart failure, n (%) | 3 (17.6) | 2.44 | 0.67–8.89 | 1 (6.3) | 0.76 | 0.10–5.91 |
| Use of OAC, n (%) | 6 (35.3) | 2.79 | 0.99–7.77 | 2 (12.5) | 0.73 | 0.16–3.28 |
| Use of APA, n (%) | 10 (58.8) | 2.88 | 1.07–7.71 | 6 (37.5) | 1.21 | 0.43–3.39 |
| Moderate Frailty, n (%) | 5 (29.4) | 1.52 | 0.36–6.52 | 7 (43.8) | 1.4 | 0.37–5.28 |
| Severe Frailty, n (%) | 9 (52.9) | 2.13 | 0.54–8.45 | 6 (37.5) | 0.93 | 0.23–3.80 |
| Polypharmacy**,. n (%) | 15 (88.2) | 3.19 | 0.72–14.1 | 8 (50.0) | 0.43 | 0.16–1.16 |
| Orthostatic hypotension, n (%) | 4 (23.5) | 1.08 | 0.26–4.39 | 6 (37.5) | 1.29 | 0.39–4.33 |
| Post prandial hypotension, n (%) | 6 (35.3) | 5.2 | 0.62–43.77 | 7 (43.8) | 2.02 | 0.51–7.99 |
| Parkinsonism, n (%) | 1 (5.9) | 0.6 | 0.08–4.65 | 2 (12.5) | 1.37 | 0.30–6.25 |
| Gait disturbance, n (%) | 7 (41.2) | 0.62 | 0.23–1.67 | 8 (50.0) | 0.89 | 0.33–2.41 |
| ADL dependence, n (%) | 3 (17.6) | 0.75 | 0.21–2.67 | 3 (18.8) | 0.81 | 0.23–2.90 |
| iADL dependence, n (%) | 6 (35.3) | 0.96 | 0.35–2.63 | 6 (37.5) | 1.05 | 0.38–2.95 |
| Cognitive impairment, n (%) | ||||||
| –MMSE < 26 points | 7 (41.2) | 2.24 | 0.83–6.03 | 7 (43.8) | 2.49 | 0.91–6.84 |
| –MoCA < 26 points | 9 (52.9) | 0.78 | 0.29–2.05 | 10 (62.5) | 1.15 | 0.41–3.22 |
| Dementia in medical history, n (%) | 1 (5.9) | 4.5 | 0.51–39.6 | 1 (6.3) | 5.1 | 0.58–45.6 |
| Presence of cerebral microbleeds, n (%) | 5 (29.4) | 0.82 | 0.28–2.41 | 6 (37.5) | 1.21 | 0.42–3.45 |
| Presence of lacunes, n (%) | 3 (17.6) | 0.69 | 0.19–2.44 | 7 (43.8) | 2.5 | 0.91–6.86 |
| Fazekas score ≥ 2, n (%) | 11 (64.7) | 1.72 | 0.63–4.74 | 13 (81.3) | 4.07 | 1.14–14.48 |
| Relevant MTA, n (%) | 10 (58.8) | 1.03 | 0.38–2.75 | 12 (75.0) | 2.15 | 0.68–6.79 |